Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)
Others
Ratios

BioLineRx (BLRX) Interest Expenses (2023 - 2025)

Historic Interest Expenses for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to -$304000.0.

  • BioLineRx's Interest Expenses rose 8129.23% to -$304000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 14439.15%. This contributed to the annual value of -$1.1 million for FY2024, which is 19808.36% down from last year.
  • As of Q3 2025, BioLineRx's Interest Expenses stood at -$304000.0, which was up 8129.23% from -$276000.0 recorded in Q2 2025.
  • BioLineRx's 5-year Interest Expenses high stood at $3.5 million for Q4 2024, and its period low was -$2.1 million during Q2 2024.
  • Its 3-year average for Interest Expenses is -$426545.5, with a median of -$837000.0 in 2023.
  • Within the past 5 years, the most significant YoY rise in BioLineRx's Interest Expenses was 44373.78% (2024), while the steepest drop was 24746.03% (2024).
  • Over the past 3 years, BioLineRx's Interest Expenses (Quarter) stood at -$1.0 million in 2023, then surged by 443.74% to $3.5 million in 2024, then tumbled by 108.65% to -$304000.0 in 2025.
  • Its Interest Expenses was -$304000.0 in Q3 2025, compared to -$276000.0 in Q2 2025 and -$420000.0 in Q1 2025.